DA 9102

Drug Profile

DA 9102

Alternative Names: Atopic dermatitis therapy - Dong-A Pharmaceutical; DA-9102

Latest Information Update: 12 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dong-A Pharmaceutical
  • Class Skin disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Atopic dermatitis

Most Recent Events

  • 12 Aug 2011 No development reported - Phase-II for Atopic dermatitis in South Korea (PO)
  • 06 Aug 2007 Phase-II clinical trials in Atopic dermatitis in South Korea (PO)
  • 15 Mar 2005 Preclinical trials in Atopic dermatitis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top